Toxicogenomics in Preclinical Development

Preclinical Development Handbook: Toxicology

Volumn , Issue , 2007, Pages 867-910

  Blomme, Eric A G ^a   Semizarov, Dimitri ^a   Waring, Jeffrey F ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Laser capture microdissection (LCM); Maximal tolerated dose (MTD); Real time reverse transcription PCR (RT PCR)

Indexed keywords

EID: 61349130111     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470249055.ch24     Document Type: Chapter

References (122)

1. Service RF. Surviving the blockbuster syndrome. Science 2004; 303: 1796-1799.
2. Grabowski HG, Vernon JM. Returns to R & D on new drug introductions in the 1980s. J Health Econ 1994; 13: 383-406.
3. Rawlings MD. Cutting the cost of drug development ? Nat Rev Drug Discov 2004; 3: 360-364.
4. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates ? Nat Rev Drug Discov 2004; 3: 711-715.
5. Prentis RA, Lis Y, Walker SR. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br J Clin Pharmacol 1988; 25: 387-396.
6. Ulrich RG, Friend SH. Toxicogenomics and drug discovery: will new technologies help us produce better drugs ? Nat Rev 2002; 1: 84-88.
7. MacNeil JS. Genomics goes downstream. Genome Technol 2005; 54: 24-30.
8. Segal E, Friedman N, Kaminski N, Regev A, Koller D. From signatures to models: understanding cancer using microarrays. Nat Genet 2005; 37 (Suppl): S38-S45.
9. Chu TM, Deng S, Wolfinger R, Paules RS, Hamadeh HK. Cross-site comparison of gene expression data reveals high similarity. Environ Health Perspect 2004; 112: 449-455.
10. Shi L, Tong W, Fang H, Scherf U, Han J, Puri RK, et al. Cross-platform comparability of microarray technology: intra-platform consistency and appropriate data analysis procedures are essential. BMC Bioinformatics 2005; 6 (Suppl 2): S12.
11. Yauk CL, Berndt ML, Williams A, Douglas GR. Comprehensive comparison of six microarray technologies. Nucleic Acids Res 2004; 32: e124.
12. Chuaqui RF, Bonner RF, Best CJ, Gillespie JW, Flaig MJ, Hewitt SM, et al. Post-analysis follow-up and validation of microarray experiments. Nat Genet 2002; 32 (Suppl): 509-514.
13. Baker VA, Harries HM, Waring JF, Duggan CM, Ni HA, Jolly RA, et al. Clofibrate-induced gene expression changes in rat liver: a cross-laboratory analysis using membrane cDNA arrays. Environ Health Perspect 2004; 112: 428-438.
14. Waring JF, Ulrich RG, Flint N, Morfitt D, Kalkuhl A, Staedtler F, et al. Interlaboratory evaluation of rat hepatic gene expression changes induced by methapyrilene. Environ Health Perspect 2004; 112: 439-448.
15. Thomas RS, Rank DR, Penn SG, Zastrow GM, Hayes KR, Hu T, et al. Applications of genomics to toxicology research. Environ Health Perspect 2002; 110: 919-923.
16. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995; 270: 467-470.
17. Nuwaysir EF, Bittner M, Trent J, Barrett JC, Afshari CA. Microarrays and toxicology: the advent of toxicogenomics. Mol Carcinog 1999; 24: 153-159.
18. Yang Y, Blomme EA, Waring JF. Toxicogenomics in drug discovery: from preclinical studies to clinical trials. Chem Biol Interact 2004; 150: 71-85.
19. Innovation or Stagnation? Challenge and Opportunity on the Critical Path to New Medical Products. Washington, DC: US Department of Health and Human Services, FDA; 2004.
20. Boess F, Kamber M, Romer S, Gasser R, Muller D, Albertini S, et al. Gene expression in two hepatic cell lines, cultured primary hepatocytes, and liver slices compared to the in vivo liver gene expression in rats: possible implications for toxicogenomics use of in vitro systems. Toxicol Sci 2003; 73: 386-402.
21. Hong Y, Muller UR, Lai F. Discriminating two classes of toxicants through expression analysis of HepG2 cells with DNA arrays. Toxicol In Vitro 2003; 17: 85-92.
22. Newton RK, Aardema M, Aubrecht J. The utility of DNA microarrays for characterizing genotoxicity. Environ Health Perspect 2004; 112: 420-422.
23. Hamadeh HK, Bushel PR, Jayadev S, Martin K, DiSorbo O, Sieber S, et al. Gene expression analysis reveals chemical-specific profiles. Toxicol Sci 2002; 67: 219-231.
24. Lee J, Richburg JH, Shipp EB, Meistrich ML, Boekelheide K. The Fas system, a regulator of testicular germ cell apoptosis, is differentially up-regulated in Sertoli cell versus germ cell injury of the testis. Endocrinology 1999; 140: 852-858.
25. Fielden MR, Eynon BP, Natsoulis G, Jarnagin K, Banas D, Kolaja KL. A gene expression signature that predicts the future onset of drug-induced renal tubular toxicity. Toxicol Pathol 2005; 33: 675-683.
26. Searfoss GH, Jordan WH, Calligaro DO, Galbreath EJ, Schirtzinger LM, Berridge BR, et al. Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J Biol Chem 2003; 278: 46107-46116.
27. Shi L, Tong W, Goodsaid F, Frueh FW, Fang H, Han T, et al. QA/QC: challenges and pitfalls facing the microarray community and regulatory agencies. Expert Rev Mol Diagn 2004; 4: 761-777.
28. Mattes WB, Pettit SD, Sansone SA, Bushel PR, Waters MD. Database development in toxicogenomics: issues and efforts. Environ Health Perspect 2004; 112: 495-505.
29. Shi L, Tong W, Su Z, Han T, Han J, Puri RK, et al. Microarray scanner calibration curves: characteristics and implications. BMC Bioinformatics 2005; 6 (Suppl 2): S11.
30. Churchill GA. Fundamentals of experimental design for cDNA microarrays. Nat Genet 2002; 32 (Suppl): 490-495.
31. Higgins MA, Berridge BR, Mills BJ, Schultze AE, Gao H, Searfoss GH, et al. Gene expression analysis of the acute phase response using a canine microarray. Toxicol Sci 2003; 74: 470-484.
32. Sugai T, Kawamura M, Iritani S, Araki K, Makifuchi T, Imai C, et al. Prefrontal abnormality of schizophrenia revealed by DNA microarray: impact on glial and neurotrophic gene expression. Ann NY Acad Sci 2004; 1025: 84-91.
33. Mirnics K, Pevsner J. Progress in the use of microarray technology to study the neurobiology of disease. Nat Neurosci 2004; 7: 434-439.
34. Galvin JE, Ginsberg SD. Expression profiling and pharmacotherapeutic development in the central nervous system. Alzheimer Dis Assoc Disord 2004; 18: 264-269.
35. Todd R, Lingen MW, Kuo WP. Gene expression profiling using laser capture microdissection. Expert Rev Mol Diagn 2002; 2: 497-507.
36. Irwin RD, Boorman GA, Cunningham ML, Heinloth AN, Malarkey DE, Paules RS. Application of toxicogenomics to toxicology: basic concepts in the analysis of microarray data. Toxicol Pathol 2004; 32: 72-83.
37. Hayes KR, Bradfield CA. Advances in toxicogenomics. Chem Res Toxicol 2005; 18: 403-414.
38. Vinciotti V, Khanin R, D'Alimonte D, Liu X, Cattini N, Hotchkiss G, et al. An experimental evaluation of a loop versus a reference design for two-channel microarrays. Bioinformatics 2005; 21: 492-501.
39. Kolaja K, Fielden M. The impact of toxicogenomics on preclinical development: from promises to realized value to regulatory implications. Preclinica 2004; 2: 122-129.
40. Fielden MR, Pearson C, Brennan R, Kolaja KL. Preclinical drug safety analysis by chemogenomic profiling in the liver. Am J Pharmacogenomics 2005; 5: 161-171.
41. Guerreiro N, Staedtler F, Grenet O, Kehren J, Chibout SD. Toxicogenomics in drug development. Toxicol Pathol 2003; 31: 471-479.
42. Ganter B, Tugendreich S, Pearson CI, Ayanoglu E, Baumhueter S, Bostian KA, et al. Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action. J Biotechnol 2005; 119: 219-244.
43. Bushel PR, Hamadeh HK, Bennett L, Green J, Ableson A, Misener S, et al. Computational selection of distinct class-and subclass-specific gene expression signatures. J Biomed Inform 2002; 35: 160-170.
44. Ellinger-Ziegelbauer H, Stuart B, Wahle B, Bomann W, Ahr HJ. Characteristic expression profiles induced by genotoxic carcinogens in rat liver. Toxicol Sci 2004; 77: 19-34.
45. Thomas RS, Rank DR, Penn SG, Zastrow GM, Hayes KR, Pande K, et al. Identification of toxicologically predictive gene sets using cDNA microarrays. Mol Pharmacol 2001; 60: 1189-1194.
46. Waring JF, Jolly RA, Ciurlionis R, Lum PY, Praestgaard JT, Morfitt DC, et al. Clustering of hepatotoxins based on mechanism of toxicity using gene expression profiles. Toxicol Appl Pharmacol 2001; 175: 28-42.
47. Waring JF, Cavet G, Jolly RA, McDowell J, Dai H, Ciurlionis R, et al. Development of a DNA microarray for toxicology based on hepatotoxin-regulated sequences. Environ Health Perspect 2003; 111: 863-870.
48. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 2001; 29: 365-371.
49. Mattes WB. Annotation and cross-indexing of array elements on multiple platforms. Environ Health Perspect 2004; 112: 506-510.
50. Luhe A, Suter L, Ruepp S, Singer T, Weiser T, Albertini S. Toxicogenomics in the pharmaceutical industry: hollow promises or real benefit ? Mutat Res 2005; 575: 102-115.
51. Tennant RW. The national center for toxicogenomics: using new technologies to inform mechanistic toxicology. Environ Health Perspect 2002; 110: 8-10.
52. Waters MD, Fostel JM. Toxicogenomics and systems toxicology: aims and prospects. Nat Rev Genet 2004; 5: 936-948.
53. Castle AL, Carver MP, Mendrick DL. Toxicogenomics: a new revolution in drug safety. Drug Discov Today 2002; 7: 728-736.
54. Searfoss GH, Ryan TP, Jolly RA. The role of transcriptome analysis in pre-clinical toxicology. Curr Mol Med 2005; 5: 53-64.
55. Suter L, Babiss LE, Wheeldon EB. Toxicogenomics in predictive toxicology in drug development. Chem Biol 2004; 11: 161-171.
56. Natsoulis G, El Ghaoui L, Lanckriet GR, Tolley AM, Leroy F, Dunlea S, et al. Classification of a large microarray data set: algorithm comparison and analysis of drug signatures. Genome Res 2005; 15: 724-736.
57. Golub TR, Slonim DK, Gaasenbeek JR, Caligiuri MA, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286: 531-537.
58. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98: 5116-5121.
59. Khan J, Wei JS, Ringner M, Saal LH, Westermann F, et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 2001; 7: 673-679.
60. Cristianini N, Shawe-Taylor J. An Introduction to Support Vector Machines. Cambridge UK: Cambridge University Press; 2000.
61. Furey TS, Cristianini N, Duffy N, Bednarski DW, Schummer M, Haussler D. Support vector machine classification and validation of cancer tissue samples using microarray expression data. Bioinformatics 2000; 16: 906-914.
62. Steiner G, Suter L, Boess F, Gasser R, de Vera MC, Albertini S, et al. Discriminating different classes of toxicants by transcript profiling. Environ Health Perspect 2004; 112: 1236-1248.
63. Thukral SK, Nordone PJ, Hu R, Sullivan L, Galambos E, Fitzpatrick VD, et al. Prediction of nephrotoxicant action and identification of candidate toxicity-related biomarkers. Toxicol Pathol 2005; 33: 343-355.
64. Greim H, Gelbke HP, Reuter U, Thielmann HW, Edler L. Evaluation of historical control data in carcinogenicity studies. Hum Exp Toxicol 2003; 22: 541-549.
65. Kramer JA, Curtiss SW, Kolaja KL, Alden CL, Blomme EA, Curtiss WC, et al. Acute molecular markers of rodent hepatic carcinogenesis identified by transcription profiling. Chem Res Toxicol 2004; 17: 463-470.
66. Ellinger-Ziegelbauer H, Stuart B, Wahle B, Bomann W, Ahr HJ. Comparison of the expression profiles induced by genotoxic and nongenotoxic carcinogens in rat liver. Mutat Res 2005; 575: 61-84.
67. Waring JF, Ulrich RG. The impact of genomics-based technologies on drug safety evaluation. Annu Rev Pharmacol Toxicol 2000; 40: 335-352.
68. Cattley RC. Peroxisome proliferators and receptor-mediated hepatic carcinogenesis. Toxicol Pathol 2004; 32 (Suppl 2): 6-11.
69. Holden PR, Tugwood JD. Peroxisome proliferator-activated receptor alpha: role in rodent liver cancer and species differences. J Mol Endocrinol 1999; 22: 1-8.
70. Hamadeh HK, Bushel PR, Jayadev S, DiSorbo O, Bennett L, Li L, et al. Prediction of compound signature using high density gene expression profiling. Toxicol Sci 2002; 67: 232-240.
71. Kramer JA, Blomme EA, Bunch RT, Davila JC, Jackson CJ, Jones PF, et al. Transcription profiling distinguishes dose-dependent effects in the livers of rats treated with clofibrate. Toxicol Pathol 2003; 31: 417-431.
72. Badr MZ, Belinsky SA, Kauffman FC, Thurman RG. Mechanism of hepatotoxicity to periportal regions of the liver lobule due to allyl alcohol: role of oxygen and lipid peroxidation. J Pharmacol Exp Ther 1986; 238: 1138-1142.
73. Butterworth KR, Carpanini FM, Dunnington D, Grasso P, Pelling D. The production of periportal necrosis by allyl alcohol in the rat. Br J Pharmacol 1978; 63: 353P-354P.
74. Amin K, Ip C, Jimenez L, Tyson C, Behrsing H. I n vitro detection of differential and cell-specific hepatobiliary toxicity induced by geldanamycin and 17-allylaminogeldanamycin using dog liver slices. Toxicol Sci 2005; 87: 442-450.
75. Waring JF, Ciurlionis R, Jolly RA, Heindel M, Ulrich RG. Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity. Toxicol Lett 2001; 120: 359-368.
76. Burczynski ME, McMillian M, Cirvo J, Li L, Parker JB, Dunn RT, et al. Toxicogenomics-based discrimination of toxic mechanism in HepG2 human hepatoma cells. Toxicol Sci 2000; 58: 399-415.
77. Gomez-Lechon MJ, Ponsoda X, Bort R, Castell JV. The use of cultured hepatocytes to investigate the metabolism of drugs and mechanisms of drug hepatotoxicity. Altern Lab Anim 2001; 29: 225-231.
78. Waring JF, Ciurlionis R, Jolly RA, Heindel M, G agne G, Fagerland JA, et al. Isolated human hepatocytes in culture display markedly different gene expression patterns depending on attachment status. Toxicol In Vitro 2003; 17: 693-701.
79. Li AP, Reith MK, Rasmussen A, Gorski JC, Hall SD, Xu L, et al. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. Chem Biol Interact 1997; 107: 17-30.
80. Ulrich RG, Bacon JA, Cramer CT, Peng GW, Petrella DK, Stryd RP, et al. Cultured hepatocytes as investigational models for hepatic toxicity: practical applications in drug discovery and development. Toxicol Lett 1995; 82-83: 107-115.
81. Liguori MJ, Anderson LM, Bukofzer S, McKim J, Pregenzer JF, Retief J, et al. Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin. Hepatology 2005; 41: 177-186.
82. de Longueville F, Surry D, Meneses-Lorente G, Bertholet V, Talbot V, Evrard S, et al. Gene expression profiling of drug metabolism and toxicology markers using a low-density DNA microarray. Biochem Pharmacol 2002; 64: 137-149.
83. Harries HM, Fletcher ST, Duggan CM, Baker VA. The use of genomics technology to investigate gene expression changes in cultured human cells. Toxicol In Vitro 2001; 15: 399-405.
84. Morgan KT, Ni H, Brown HR, Yoon L, Crosby LM, et al. Application of cDNA microarray technology to in vitro toxicology and the selection of genes for a real-time RT-PCR-based screen for oxidative stress in Hep-G2 cells. Toxicol Pathol 2002; 30: 435-451.
85. Aubrecht J, Caba E. Gene expression profile analysis: an emerging approach to investigate mechanisms of genotoxicity. Pharmacogenomics 2005; 6: 419-428.
86. Snyder RD, Green JW. A review of the genotoxicity of marketed pharmaceuticals. Mutat Res 2001; 488: 151-169.
87. Dickinson DA, Warnes GR, Quievryn G, Messer J, Zhitkovich A, Rubitski E, et al. Differentiation of DNA reactive and non-reactive genotoxic mechanisms using gene expression profile analysis. Mutat Res 2004; 549: 29-41.
88. Yang Y, Abel S, Ciurlionis R, Waring JF. Development of gene expression-based in vitro assays for the efficient toxicity characterization of compounds. Pharmacogenomics 2006; 7: 177-186.
89. Waring JF, Gum R, Morfitt D, Jolly RA, Ciurlionis R, Heindel M, et al. Identifying toxic mechanisms using DNA microarrays: evidence that an experimental inhibitor of cell adhesion molecule expression signals through the aryl hydrocarbon nuclear receptor. Toxicology 2002; 181-182: 537-550.
90. Denison MS, Nagy SR. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol 2003; 43: 309-334.
91. Milano J, McKay J, Dagenais C, Foster-Brown L, Pognan F, Gadient R, et al. Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci 2004; 82: 341-358.
92. Creasy DM. Evaluation of testicular toxicity in safety evaluation studies: the appropriate use of spermatogenic staging. Toxicol Pathol 1997; 25: 119-131.
93. Stewart J. Inhibin B as a potential biomarker of testicular toxicity. Toxicologist 2005; 74: 6.
94. Richburg JH, Johnson KJ, Schoenfeld HA, Meistrich ML, Dix DJ. Defining the cellular and molecular mechanisms of toxicant action in the testis. Toxicol Lett 2002; 135: 167-183.
95. Adachi T, Ono Y, Koh KB, Takashima K, Tainaka H, Matsuno Y, et al. Long-term alteration of gene expression without morphological change in testis after neonatal exposure to genistein in mice: toxicogenomic analysis using cDNA microarray. Food Chem Toxicol 2004; 42: 445-452.
96. Adachi T, Koh KB, Tainaka H, Matsuno Y, Ono Y, Sakurai K, et al. Toxicogenomic difference between diethylstilbestrol and 17beta-estradiol in mouse testicular gene expression by neonatal exposure. Mol Reprod Dev 2004; 67: 19-25.
97. Rockett JC, Christopher LJ, Brian GJ, Krawetz SA, Hughes MR, Hee KK, et al. Development of a 950-gene DNA array for examining gene expression patterns in mouse testis. Genome Biol 2001; 2: 14.1-14.9.
98. Zappa F, Ward T, Pedrinis E, Butler J, McGown A. NAD(P)H: quinone oxidoreductase 1 expression in kidney podocytes. J Histochem Cytochem 2003; 51: 297-302.
99. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci USA 2004; 101: 6062-6067.
100. Su AI, Cooke MP, Ching KA, Hakak Y, Walker JR, Wiltshire T, et al. Large-scale analysis of the human and mouse transcriptomes. Proc Natl Acad Sci USA 2002; 99: 4465-4470.
101. Honore P, Kage K, Mikusa J, Watt AT, Johnston JF, Wyatt JR, et al. Analgesic profile of intrathecal P2X(3) antisense oligonucleotide treatment in chronic inflammatory and neuropathic pain states in rats. Pain 2002; 99: 11-19.
102. Semizarov D, Frost L, Sarthy A, Kroeger P, Halbert DN, Fesik SW. Specificity of short interfering RNA determined through gene expression signatures. Proc Natl Acad Sci USA 2003; 100: 6347-6352.
103. Zambrowicz BP, Turner CA, Sands AT. Predicting drug efficacy: knockouts model pipeline drugs of the pharmaceutical industry. Curr Opin Pharmacol 2003; 3: 563-570.
104. Lu PY, Xie F, Woodle MC. In vivo application of RNA interference: from functional genomics to therapeutics. Adv Genet 2005; 54: 117-142.
105. Li L, Lin X, Staver M, Shoemaker A, Semizarov D, Fesik SW, et al. Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res 2005; 65: 7249-7258.
106. Waring JF, Anderson MG. Idiosyncratic toxicity: mechanistic insights gained from analysis of prior compounds. Curr Opin Drug Discov Dev 2005; 8: 59-65.
107. Williams DP, Park BK. Idiosyncratic toxicity: the role of toxicophores and bioactivation. Drug Discov Today 2003; 8: 1044-1050.
108. Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndrome. Lancet 2000; 356: 1587-1591.
109. Uetrecht J. Prediction of a new drug's potential to cause idiosyncratic reactions. Curr Opin Drug Discov Dev 2001; 4: 55-59.
110. Roth RA, Luyendyk JA, Maddox JF, Ganey PE. Inflammation and drug idiosyncrasy-is there a connection ? J Exp Ther 2003; 307: 1-8.
111. Park BK, Kitteringham NR, Powell H, Pirmohamed M. Advances in molecular toxicology-towards understanding idiosyncratic drug toxicity. Toxicology 2000; 153: 39-60.
112. Shenton JM, Teranishi M, Abu-Asab MS, Yager JA, Uetrecht JP. Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat. Chem Res Toxicol 2003; 16: 1078-1089.
113. Masson MJ, Uetrecht JP. Tolerance induced by low dose d-penicillamine in the brown Norway rat model of drug-induced autoimmunity is immune-mediated. Chem Res Toxicol 2004; 17: 82-94.
114. Luyendyk JP, Maddox JF, Cosma GN, Ganey PE, Cockerell GL, Roth RA. Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. J Pharmacol Exp Ther 2003; 307: 9-16.
115. Buchweitz JP, Ganey PE, Bursian SJ, Roth RA. Underlying endotoxemia augments toxic responses to chlorpromazine: is there a relationship to drug idiosyncrasy ? J Pharmacol Exp Ther 2002; 300: 460-467.
116. Waring JF, Liguori MJ, Luyendyk JP, Maddox JF, Ganey PE, Stachlewitz RF, et al. Microarray analysis of LPS potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils. J Pharmacol Exp Ther 2006; 316: 1080-1087.
117. Luyendyk JP, Mattes WB, Burgoon LD, Zacharewski TR, Maddox JF, Cosma GN, et al. Gene expression analysis points to hemostasis in livers of rats cotreated with lipopolysaccharide and ranitidine. Toxicol Sci 2004; 80: 203-213.
118. Tirmenstein MA, Hu CX, Gales TL, Maleeff BE, Narayanan PK, Kurali E, et al. Effects of troglitazone on HepG2 viability and mitochondrial function. Toxicol Sci 2002; 69: 131-138.
119. Drlica K, Zhao X. DNA gyrase, topoisomerase IV and the;4-quinolones. Microbiol Mol Biol Rev 1997; 61: 377-392.
120. Ball P, Mandell L, Niki Y, Tillotson G. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Safety 1999; 21: 407-421.
121. Bertino J, Fish D. The safety profile of the fluoroquinolones. Clin Ther 2000; 22: 798-817.
122. Kier LD, Neft R, Tang L, Suizu R, Cook T, Onsurez K, et al. A pplications of microarrays with toxicologically-relevant genes (tox genes) for the evaluation of chemical toxicants in Sprague Dawley rats in vivo and human hepatocytes in vitro. Mutat Res 2004; 549: 101-113.